Trial Profile

First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PHN 010 (Primary)
Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Pheon Therapeutics

Most Recent Events

19 Aug 2025 Status changed from recruiting to active, no longer recruiting.
15 Jul 2024 Status changed from not yet recruiting to recruiting.
19 Jun 2024 According to a Clarivate Plc media release, HN-010 is set to enter the clinical stage in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com